Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03303456 · ClinicalTrials.gov registry record · NA

Using Mobile Technology to Enhance Early Psychosis Treatment Delivery

A NA study, sponsored by University of California, Davis.

Completed
Registry status
NA
Development phase
79
Enrollment target

NCT03303456 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 79 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03303456, a NA study, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
NA
Development phase
79 participants
Enrollment target

Study Summary

This project tests the feasibility of implementing a smartphone application - Ginger.io - in the UC Davis Early Psychosis Program, and investigates whether mobile health technology can improve treatment delivery and outcomes in individuals with early psychosis. Ginger.io is a smartphone application that utilizes methods of passive data collection (i.e. data gathered without active interaction/contribution from the user) to gather communication, movement, and interaction data from smartphone devices to model individuals' social, physical, and mental health. These models are used to infer health-related outcomes and could inform treatment. By implementing the Ginger.io application in the UC Davis Early Psychosis Program with an integrated clinical and research infrastructure, the investigators will be able to quickly determine its feasibility for use in early psychosis populations, while simultaneously developing its ability to systematically capture aspects of relapse and recovery that are unique to this patient population. Objectives: This project has three principle objectives related to early psychosis care: 1) improve treatment delivery, 2) improve patient outcomes, and 3) lower treatment costs. The project will target individuals in the early stages of psychotic illness, including individuals at high risk for developing a psychotic illness (termed "clinical high risk" or CHR) and individuals within three years of their first psychotic episode (termed "first episode psychosis" or FEP). The early stages of psychotic illness represent a critical period for intervention; early identification of clinical deterioration and subsequent targeted intervention is crucial for rapid remission of symptoms and reduced relapse rates. However, without the information necessary to identify patients in need of such intervention, providers are limited in their ability to respond rapidly. Within the UCD Early Psychosis Program, a mobile health application such as Ginger.io has the

Interventions

  • OTHER Mobile health application - Ginger.io

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2014-12-14
Est. Completion 2015-11-01
Phase NA

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT03303456

The ClinicalTrials.gov registry entry for NCT03303456 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mobile health application - Ginger.io is the first listed.

NCT03303456 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03303456 about?

NCT03303456 is a clinical study titled "Using Mobile Technology to Enhance Early Psychosis Treatment Delivery". This project tests the feasibility of implementing a smartphone application - Ginger.io - in the UC Davis Early Psychosis Program, and investigates whether mobile health technology can improve treatment delivery and outcomes in individuals with early psychosis. Ginger.io is a smartphone application ...

What is the current status of trial NCT03303456?

This trial is currently completed. It is a NA study. The enrollment target is 79 participants. The study started on 2014-12-14. Estimated completion is 2015-11-01.

What interventions are being tested in trial NCT03303456?

The interventions under investigation include: Mobile health application - Ginger.io (OTHER).

Who is sponsoring clinical trial NCT03303456?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.